Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism

Vascular Health and Risk Management

Volumn 11, Issue , 2015, Pages 343-351

  Chan, Noel C ^a,b   Bhagirath, Vinai ^a,c   Eikelboom, John W ^a,c,d  

^a MCMASTER UNIVERSITY   (Canada)

^b MONASH MEDICAL CENTRE   (Australia)

^c MCMASTER UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulant; Betrixaban; Factor Xa inhibitors; Pharmacology; Venous thromboembolism

Indexed keywords

APIXABAN; BETRIXABAN; DABIGATRAN; EDOXABAN; ENOXAPARIN; RIVAROXABAN; WARFARIN; BENZAMIDE DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN; PYRIDINE DERIVATIVE; VITAMIN K GROUP;

ARTERY THROMBOSIS; ATRIAL FIBRILLATION; BABOON; BLEEDING; CEREBROVASCULAR ACCIDENT; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; EX VIVO STUDY; HUMAN; IN VITRO STUDY; LIVER TOXICITY; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QT PROLONGATION; RABBIT MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RODENT MODEL; THROMBOSIS PREVENTION; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VOMITING; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; BENZAMIDES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE MODELS, ANIMAL; FACTOR XA INHIBITORS; HEPARIN; HUMANS; PYRIDINES; VENOUS THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 84936761917     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S63060     Document Type: Review

References (42)

1. Rathbun S. The surgeon general’s call to action to prevent deep vein thrombosis and pulmonary embolism. Circulation. 2009;119(15):e480–e482.
2. Office of the Surgeon General (US), National Heart Lung, and Blood Institute (US). The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Rockville (MD): Office of the Surgeon General (US); 2008. Available from: http://www.ncbi.nlm.nih.gov/books/NBK44178/. Accessed April 8, 2015.
3. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2_Suppl):e152S–e84S.
4. Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2013;2013:464–470.
5. Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood. 2014;124(7): 1020–1028.
6. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24):2342–2352.
7. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764–772.
8. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26): 2499–2510.
9. Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366(14):1287–1297.
10. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.
11. Buller HR, Decousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–1415.
12. Connolly SJ, Eikelboom J, Dorian P, et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J. 2013;34(20): 1498–1505.
13. Turpie AG, Bauer KA, Davidson BL, et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost. 2009;101(1):68–76.
14. Cohen AT, Harrington R, Goldhaber SZ, et al. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) Study. Am Heart J. 2014;167(3):335–341.
15. Zhang P, Huang W, Wang L, et al. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N, N-dimethylcarbamimidoyl)benzamido)-5-methoxybenz amide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett. 2009;19(8): 2179–2185.
16. Sinha U, Edwards ST, Wong PW, et al. Antithrombotic activity of PRT54021, a potent oral direct factor Xa inhibitor, can be monitored using a novel prothrombinase inhibition bioassay. Blood. 2006;108(11): 272A–A.
17. Abe K, Siu G, Edwards S, et al. Animal models of thrombosis help predict the human therapeutic concentration of PRT54021, a potent oral factor Xa inhibitor. Blood. 2006;108(11):270A–A.
18. ClinicalTrials.gov. NCT01765868: A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers 2012; 2015 [cited July 31, 2013]. Available from: http://clinicaltrial.gov/ct2/show/NCT01765868?term=betrixaban&rank=5. Accessed 8 April, 2015.
19. ClinicalTrials.gov. NCT01765855: An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects; 2015. Available from: http://clinicaltrial.gov/ct2/show/NCT01765855?term=betrixaban&rank=6. Accessed April 8, 2015.
20. Hutchaleelaha A, Ye C, Song Y, Lorenz T, Gretler D, Lambing JL. Metabolism and disposition of betrixaban and its lack of interaction with major CYP enzymes. ASH Annu Meet Abstr. 2012;120(21):2266.
21. Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40(12):2250–2255.
22. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386–399.
23. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2009;37(5):1056–1064.
24. Zhang D, He K, Raghavan N, et al. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos. 2009;37(8):1738–1748.
25. Morganroth J, Gretler DD, Hollenbach SJ, Lambing JL, Sinha U. Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo-and positive-controlled thorough ECG study. Expert Opin Pharmacother. 2013;14(1):5–13.
26. ClinicalTrials.gov. NCT01583218: Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study); 2015. Available from: http://clinicaltrial.gov/ct2/show/NCT01583218?term=betrixaban&rank=3. Accessed April 8, 2015.
27. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153(1):8–18.
28. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167–2177.
29. Cohen AT, Spiro TE, Buller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513–523.
30. Cohen AT, Harrington R, Goldhaber SZ, et al. Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment. Am Heart J. 2015;169(1):186–187.
31. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua prediction score. J Thromb Haemost. 2010;8(11):2450–2457.
32. Spyropoulos AC, Anderson FA Jr, Fitzgerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140(3):706–714.
33. Woller SC, Stevens SM, Jones JP, et al. Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. Am J Med. 2011;124(10):947–954. e2.
34. Rosenberg D, Eichorn A, Alarcon M, McCullagh L, McGinn T, Spyropoulos AC. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc. 2014;3(6):e001152.
35. Cohen AT, Spiro TE, Spyropoulos AC, et al. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost. 2014;12(4):479–487.
36. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446–451.
37. Crowther MA, Kitt M, McClure M, et al. Randomized, double-blind, placebo-controlled single ascending dose pharmacokinetic and pharmacodynamic study of PRT064445, a universal antidote for factor Xa inhibitors (abstract). Arterioscler Thromb Vasc Biol. 2013;33:A10.
38. Crowther MA, Mathur V, Kitt M, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors (abstract). Blood. 2013;122:A3636.
39. Crowther MA, Kitt M, Lorenz T, et al. A phase 2 randomized, double-blind, placebo-controlled trial of PRT4445, a novel, universal antidote for direct and indirect Factor Xa inhibitors (abstract). J Thromb Haemost. 2013;11:AS20.1.
40. Crowther M, Levy G, Lu G, et al. ANNEXA™ A: a Phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of apixaban-induced anticoagulation in older subjects by Andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors (abstract). Circulation. 2014;130:2105–2126.
41. Hollenbach S, Tan S, DeGuzman F, et al. PRT064445 reverses rivaroxaban induced antiacogulation in a rabbit liver laceration treatment model (abstract). Eur Heart J. 2013;34:24.
42. Hollenbach S, Lu G, DeGuzman F, et al. Abstract 14657: andexanet-alfa and PER977 (Arapazine) correct blood loss in a rabbit liver laceration model–only andexanet reverses markers of fXa-mediated anticoagulation. Circulation. 2014;130(Suppl 2):A14657.